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Background and Purpose—Bridging therapy with low-molecular-weight heparin reportedly leads to a worse outcome 
for acute cardioembolic stroke patients because of a higher incidence of intracerebral bleeding. However, this practice 
is common in clinical settings. This observational study aimed to compare (1) the clinical profiles of patients receiving 
and not receiving bridging therapy, (2) overall group outcomes, and (3) outcomes according to the type of anticoagulant 
prescribed.
Methods—We analyzed data of patients from the prospective RAF and RAF-NOACs studies. The primary outcome was 
defined as the composite of ischemic stroke, transient ischemic attack, systemic embolism, symptomatic cerebral bleeding, 
and major extracerebral bleeding observed at 90 days after the acute stroke.
Results—Of 1810 patients who initiated oral anticoagulant therapy, 371 (20%) underwent bridging therapy with full-dose 
low-molecular-weight heparin. Older age and the presence of leukoaraiosis were inversely correlated with the use of 
bridging therapy. Forty-two bridged patients (11.3%) reached the combined outcome versus 72 (5.0%) of the nonbridged 
patients (P=0.0001). At multivariable analysis, bridging therapy was associated with the composite end point (odds ratio, 
2.3; 95% CI, 1.4–3.7; P<0.0001), as well as ischemic (odds ratio, 2.2; 95% CI, 1.3–3.9; P=0.005) and hemorrhagic (odds 
ratio, 2.4; 95% CI, 1.2–4.9; P=0.01) end points separately.
Conclusions—Our findings suggest that patients receiving low-molecular-weight heparin have a higher risk of early 
ischemic recurrence and hemorrhagic transformation compared with nonbridged patients.   (Stroke. 2019;50:2093-2100. 
DOI: 10.1161/STROKEAHA.118.022856.)
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Oral anticoagulant therapy (OAC) is the treatment of choice for secondary prevention of stroke in patients 
with nonvalvular atrial fibrillation (AF). For this indication, 
the currently approved OACs are vitamin K antagonists 
(VKAs) and non–VKA oral anticoagulants (NOACs). VKAs 
are slower than NOACs in reaching the therapeutic anticoag-
ulant effect, as their mechanism of action is the inhibition of 
vitamin K–dependent coagulation factors, which requires few 
days. The effect of VKAs is measured through the interna-
tional normalized ratio that, as reflects the activity of VKA, 
requires few days to reach the therapeutic target. In some 
cases, a temporary therapy with full-dose low-molecular-
weight heparin (LMWH) can be given alongside warfarin 
until the therapeutic international normalized ratio level is 
achieved. Moreover, bridging therapy is used to counteract 
the transient prothrombotic effect in the initial phase of OAC 
treatment.1
The advantages of NOACs are their rapidity of action (2–3 
hours for dabigatran, 2–4 hours for rivaroxaban, 3–4 hours 
for apixaban, and 1–2 hours for edoxaban) and fast reversal, 
similar to heparin in that respect. Moreover, their standard 
dosages do not require titration, whereas VKAs do.
Despite evidence that full-dose LMWH can be harmful in 
acute stroke care2 in particular in the presence of AF,3 there 
are anecdotal reports of its use in selected patients.4,5 Mostly, 
acute heparin treatment is used as bridging therapy until the 
therapeutic range of OACs is achieved—the so-called bridg-
ing therapy.1
By using data from the prospective RAF6 and RAF-
NOACs7 studies, we aimed to evaluate (1) the clinical profiles 
of patients who received or not bridging therapy, (2) differ-
ences in outcomes between these 2 groups, and (3) differences 
in outcomes according to the type of OAC prescribed.
Patients and Methods
We analyzed the data of patients from the prospective RAF 
(Early Recurrence and Cerebral Bleeding in Patients With 
Acute Ischemic Stroke and Atrial Fibrillation) and RAF-
NOACs (Early Recurrence and Major Bleeding in Patients 
With Acute Ischemic Stroke and Atrial Fibrillation Treated 
With Non-Vitamin-K Oral Anticoagulants) studies that 
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enrolled consecutive patients with acute ischemic stroke 
and nonvalvular AF. The methods and results of the RAF 
studies have been previously described in detail,6,7 and the 
data are available from the corresponding author on reason-
able request. Both studies were approved by the local insti-
tutional review board if required. Patient exclusion criteria 
for both studies were high risk of bleeding, defined as clin-
ically significant liver disease (acute or chronic hepatitis, 
cirrhosis, or alanine aminotransferase level >3× the upper 
limit of normality), creatinine clearance <30 mL/min (for 
apixaban, the threshold was 25 mL/min), life expectancy of 
<3 to 6 months, the presence of uncontrolled hypertension,8 
and the ongoing prescription of medications having known 
metabolic interactions with any type of OACs.
A noncontrast cerebral computed tomography (CT) or 
cerebral magnetic resonance scan was performed on admis-
sion for each patient, to exclude for the presence of intracra-
nial hemorrhage. Thrombolysis treatment was administered 
according to standard protocol, when appropriate. All of the 
participating centers provided stroke unit care according to 
current international recommendations for acute ischemic 
stroke treatment.9,10 Stroke physicians were free to make deci-
sions on the type of anticoagulant to be used for secondary 
prevention, as well as its starting time.
Nonvalvular AF was classified as paroxysmal (episodes 
terminating spontaneously within 7 days), persistent (episodes 
lasting >7 days requiring pharmacological or electrical stim-
ulation), or permanent (persisting for >1 year, either because 
cardioversion failed or had not been attempted).11
A second brain CT scan or magnetic resonance was per-
formed 24 to 72 hours from stroke onset for all patients. 
Hemorrhagic transformation (HT) was defined on CT 
scan as any degree of hyperdensity within the area of low 
attenuation and was classified as either hemorrhagic in-
farction or parenchymal hematoma.12,13 On magnetic reso-
nance imaging, HT was defined as hypointensity on axial 
T1-weighted or T2-weighted images. HT was considered 
to be symptomatic if it was associated with an increase of 
≥4 points in the National Institutes of Health Stroke Scale 
(NIHSS), score and there was no evidence of intracranial 
bleeding on the first CT.14 The sites and sizes of the qualify-
ing infarcts were determined based on standard templates15,16 
as (1) small, when a lesion was ≤1.5 cm in the anterior or 
posterior circulation; (2) medium, when a lesion was in a 
superficial cortical branch of middle cerebral artery (MCA), 
in the MCA deep branch, in the internal border zone terri-
tories, in a cortical superficial branch of posterior cerebral 
artery, in a cortical superficial branch of the anterior cerebral 
artery; (3) large anterior, when a lesion involved the com-
plete territory of MCA, posterior cerebral artery, or anterior 
cerebral artery, in 2 superficial cortical branches of MCA, in 
a cortical superficial branch of MCA associated to the MCA 
deep branch, or in >1 artery territory (eg, MCA associated to 
anterior cerebral artery territories); and (4) large posterior, 
when a lesion was ≥1.5 cm in the brain stem or cerebellum.13
For the purpose of this analysis, bridging therapy was de-
fined as any temporary full dose of LMWH (eg, 100 UI/kg of 
enoxaparin twice a day) started together before or with VKAs, 
to cover the time needed by the latter to reach the therapeutic 
effect1 or as any full dose (given for at least 24 hours) of 
LMWH before the use of an NOAC.
Risk Factors
Data on stroke risk factors were collected as described previ-
ously6,7: age, sex, history of hypertension (blood pressure of 
≥140/90 mm Hg at least twice before stroke or already under 
treatment with antihypertensive drugs), history of diabetes 
mellitus (fasting serum glucose level ≥126 mg/dL preprandial 
on 2 examinations, glucose level ≥200 mg/dL postprandial, 
or glycated haemoglobin ≥6.5%, or under antidiabetic treat-
ment), current cigarette smoking, past smoking (cessation 
<5 years ago), hyperlipidemia (total cholesterol ≥200 mg/dL 
or triglyceride ≥140 mg/dL or already under lipid-lowering 
therapy), history of symptomatic ischemic heart disease (my-
ocardial infarction, history of angina or existence of multiple 
lesions on thallium heart isotope scan or evidence of coro-
nary disease on coronary angiography), history of sympto-
matic peripheral artery disease (intermittent claudication of 
presumed atherosclerotic origin or ankle/arm systolic blood 
pressure ratio <0.85 in either leg at rest or history of intermit-
tent claudication with previous leg amputation, reconstructive 
surgery, or angioplasty), alcohol abuse (≥300 g per week), 
obesity (body mass index ≥30 kg/m2), or previous stroke/
transient ischemic attack (TIA) White matter changes (leuko-
araiosis) defined on the first CT (or magnetic resonance im-
aging) examination as ill defined and moderately hypodense 
(or hyperintensity on T2 weighted on magnetic resonance im-
aging) areas of ≥5 mm according to published criteria were 
investigated.17 Leukoaraiosis in the deep white matter was 
dichotomized into absent versus mild, moderate, or severe. 
Other baseline variables obtained at admission for all patients 
included fasting serum glucose, fasting serum cholesterol 
(total, HDL [high-density lipoprotein], and LDL [low-density 
lipoprotein]), platelet count, international normalized ratios, 
activated partial thromboplastin time, systolic blood pressure, 
and diastolic blood pressure.
Data on the use of any antiplatelet, anticoagulants, or 
thrombolytic agent, before admission, at baseline, and during 
the follow-up period, were recorded.
The CHA2DS2-VASc score was calculated before and after 
the index event.18
Evaluation of Outcomes
Patients were followed up prospectively through face-to-face 
or telephone interviews. Study outcomes at 90 days were (1) 
recurrent ischemic cerebrovascular events (stroke or TIA) or 
symptomatic systemic embolisms; (2) symptomatic cerebral 
bleedings or major extracerebral bleedings.
The primary study outcome was the composite of stroke, 
TIA, systemic embolism, symptomatic cerebral bleeding, and 
major extracerebral bleeding.6,7 HTs found on neuroimaging 
24 to 72 hours after onset were not considered outcome events 
unless classified as symptomatic.
Stroke was defined as the sudden onset of a new focal 
neurological deficit of vascular origin in a site consistent 
with the territory of a major cerebral artery and catego-
rized as ischemic or hemorrhagic. TIA was defined as a 
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transient episode of neurological dysfunction caused by 
focal brain ischemia without acute infarction. Systemic 
embolism was defined as an acute vascular occlusion of 
an extremity or organ confirmed by imaging, surgery, or 
autopsy. Cerebral bleeding was considered symptomatic 
if associated with a decline in neurological status (an 
increase of ≥4 points in the NIHSS score or leading to 
death). Major extracerebral bleeding was defined as a re-
duction in the hemoglobin level of at least 2 g/dL, requir-
ing blood transfusion of at least 2 units, or symptomatic 
bleeding in a critical area or organ.19
Disability and mortality at 90 days were also assessed 
using the modified Rankin Scale. Nondisabling functional 
outcome was defined as an modified Rankin Scale score of 
0 to 2.
Statistical Analysis
Differences in patient characteristics between the 2 groups 
(bridging versus nonbridging therapy) were assessed utilizing 
the χ2 test. Univariable analysis was performed to compare 
clinical features at admission and their risk factors. The 2 con-
tinuous variables, NIHSS score and age, are reported as mean 
values and SDs, whereas categorical variables are reported as 
percentages.
Multivariable logistic regression was performed to in-
vestigate independent variables and their possible correla-
tions with the bridging therapy. The variables included in the 
model were NIHSS score, the presence of diabetes mellitus, 
arterial hypertension, dyslipidemia, paroxysmal AF, pace-
maker; lesion size, leukoaraiosis, CHA2DS2-VASc score 
after the event, as well as the histories of stroke or TIA, cur-
rent smoking habit, congestive heart failure, and myocardial 
infarction.
Univariable analysis was used to compare the combined 
outcomes of the 2 groups, for recurrence of ischemic stroke 
and occurrence of bleeding. The same analysis was performed 
to compare the combined outcomes of the 2 OAC regimens.
Given the difference of numbers of patients in the 2 groups, 
and the possible presence of confounding factors influencing 
outcomes, a propensity score (PS) matching was also per-
formed, and outcomes were evaluated in the 2 groups, each 
of 323 patients, obtained after matching20; the PS is the prob-
ability that a patient would have been treated with bridging 
therapy with LMWH given his pretreatment variables. Equal 
PS values guarantee equal distribution of measured pretreat-
ment variables at baseline on the sample level; thus, PS is an 
attempt to create homogeneous groups for comparison when 
data from a randomization procedure are not available. The in-
dividual PSs for analyzing bridging and nonbridging therapy 
groups were estimated with a logit model including the fol-
lowing variables: age, sex, NIHSS at admission, vascular risk 
factors, lesion size, use of NOACs, and CHA2DS2-VASc. To 
estimate treatment effects, Cox proportional hazards mod-
els were performed on the entire cohort to derive crude and 
PS-adjusted hazard ratios (HRs).
The observed correlation between the combined outcome 
(survival) and the set of variables was analyzed using the pro-
portional Cox model; here, all the variables included in our 
multivariable analysis were used. Patients were censored at 
the time of an outcome event, death, or lost during follow-up.
Results
A total of 2164 patients were enrolled in the RAF (n=1037) 
and RAF-NOACs (n=1127) studies. Patients who did not start 
any anticoagulation were excluded, as well as those who were 
treated only with LMWH. This resulted in 1821 patients, of 
whom another 11 were excluded because of incomplete data 
related to the administration of OAC therapy. A further 30 
patients were lost during follow-up.
After index acute ischemic stroke, 371 of 1810 patients 
(20.49%) underwent bridging therapy with LMWH (Figure I 
in the online-only Data Supplement).
OAC was initiated with warfarin in 561 of 1780 patients 
(31.52%), and NOACs were started in 1219 of 1780 (68.48%). 
The median for initiating bridging therapy was 7 days (inter-
quartile range, 11), whereas for the nonbridging group, this 
number was a median of 8 days (interquartile range, 14). 
Mean NIHSS at admission was 7.2±6.3 in the bridging group 
and 7.7±6.2 in the nonbridging group (P=NS).
Table 1. Clinical Characteristics of Study Patients (n=1810)
Clinical Characteristics of 
Patients (n=1810)
Bridging 
Therapy 
(n=371)
Nonbridging 
Therapy 
(n=1439) P Value
Age, y 73.0±9.7 76.1±9.4 0.0001
Male sex 197 (53.1%) 663 (46.1%) 0.017
NIHSS at admission 7.2±6.3 7.7±6.2 NS
Diabetes mellitus 80 (21.6%) 297 (20.6%) NS
Hypertension 275 (74.1%) 1124 (78.1%) NS
Dyslipidemia 118 (31.8%) 510 (35.4%) NS
Paroxysmal AF 153 (41.2%) 656 (45.6%) NS
Smoking habit 46 (12.4%) 140 (9.7%) NS
History of stroke/TIA 84 (22.6%) 382 (26.5%) NS
History of CHF 74 (19.9%) 232 (16.0%) NS
History of MI 48 (12.9%) 183 (12.7%) NS
History of PAD 40 (10.8%) 116 (8.1%) NS
PMK 21 (5.7%) 93 (6.5%) NS
HT, 24–72 h 40 (10.8%) 135 (9.4%) NS
Poststroke CHA
2
DS
2
-VASc >4 255 (68.7%) 1094 (76.0%) 0.03
Antiplatelet therapy 41 (11.0%) 200 (13.9%) NS
Cerebral infarct pattern
  Small 153 (41.2%) 582 (40.4%) NS
  Medium 153 (41.2%) 469 (32.6%) 0.010
  Large anterior circulation 41 (11.1%) 232 (16.1%) 0.006
  Large posterior circulation 15 (4.0%) 92 (6.4%) NS
  Leukoaraiosis 143 (38.5%) 786 (54.6%) 0.0001
AF indicates atrial fibrillation; CHF, congestive heart failure; HT, hemorrhagic 
transformation; MI, myocardial infarction; NIHSS, National Institutes of Health 
Stroke Scale; NS, nonsignificant; PAD, peripheral artery disease; PMK, 
pacemaker; and TIA, transient ischemic attack.
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Clinical Characteristics of the Bridging 
and Nonbridging Groups
The bridging and nonbridging groups differed for age, sex, the 
percentage of medium-sized lesions, of large anterior circula-
tion lesions, and for the presence of leukoaraiosis (Table 1). 
The mean ages were 73.0±9.7 versus 76.1±9.4 years, respec-
tively (P<0.001). Of the 371 bridging patients, 197 (53.1%) 
were male, versus 663 males (46.1%) in the nonbridging 
group (P=0.017). In the bridging group, 153 patients (41.2%) 
had medium-sized lesions versus 469 (32.6%) in the non-
bridging group (P=0.010); large anterior lesions were present 
in 41 (11.1%) of bridging patients and 232 (16.1%) nonbridg-
ing patients (P=0.006). Leukoaraiosis was diagnosed in 143 
(38.5%) and 786 (54.6%) patients, respectively (P=0.001).
Forty-one of 371 (11.0%) in the bridging group were si-
multaneously taking an antiplatelet agent (either aspirin, 100 
mg per day, or clopidogrel, 75 mg per day), whereas in the 
nonbridging group, patients under antiplatelet therapy were 
200 of 1439 (13.9%), being statistically similar (P=0.2).
At multivariable analysis, age (odds ratio [OR], 0.97; 95% 
CI, 0.95–0.98; P=0.001) and leukoaraiosis (OR, 0.60; 95% CI, 
0.47–0.78; P=0.001) were inversely correlated with the use of 
bridging therapy (Table I in the online-only Data Supplement).
Outcomes in the Bridging and Nonbridging Groups
Overall, 42 of 371 bridging patients (11.3%) experienced 
the combined outcome, compared with 72 of 1409 in the 
nonbridged group (5.1%; P=0.0001). Within the bridging 
group, 29 of 42 (69%, 7.8% of all outcomes) versus 44 of 72 
(61.11%, 3.1% of all outcomes) in the nonbridging group had 
an ischemic stroke, respectively. Major bleedings occurred in 
19 of 42 patients (45.23%, 5.1% of all outcomes) in the bridg-
ing group and 32 of 72 (44.44%, 2.3% of all outcomes) in the 
nonbridging group (P=0.08; Table 2).
In the multivariable analysis, bridging therapy was as-
sociated with combined outcome (OR, 2.3; 95% CI, 1.4–
3.7; P<0.0001), ischemic event (OR, 2.2; 95% CI, 1.3–3.9; 
P=0.005), and hemorrhagic event (OR, 2.4; 95% CI, 1.2–4.9; 
P=0.01; Table 3).
PS matching was performed on 323 patients in each 
group. The 2 groups were comparable for age (74.3±8.7 years 
in the nonbridging group versus 74.0±8.5 years in the bridg-
ing group; P=0.7), sex (170 men, 52.6% of the total, in the 
nonbridging group versus 161 males, 49.8% of the total, in 
the bridging group; P=0.5), and NIHSS at admission (7.5±6.3 
versus 7.6±6.3); also, they were comparable for clinical 
characteristics; NOACs were used as anticoagulants in 114 
patients (35.3%) in the nonbridging group versus 115 patients 
(35.6%) in the bridging group (P=1.0; Table II in the online-
only Data Supplement).
The PS analysis confirmed the results of the multivariable 
analysis; bridging therapy was associated with combined out-
come (HR, 3.08; 95% CI, 1.68–5.64; P<0.001), ischemic event 
(HR, 4.50; 95% CI, 1.88–10.75; P<0.003), and hemorrhagic 
event (HR, 2.71; 95% CI, 1.16–6.37; P=0.017; Table 4); the 
same results were confirmed after the PS was adjusted for age, 
sex, NIHSS at admission, vascular risk factors, lesion size, 
and CHA2DS2-VASc: combined outcome had an HR of 2.23 
(95% CI, 1.41–3.52; P<0.001), ischemic event, an HR of 2.23 
(95% CI, 1.29–3.88; P<0.003), and hemorrhagic event, an HR 
of 2.24 (95% CI, 1.15–4.36; P=0.017; Table 4).
In Figure II in the online-only Data Supplement, the cu-
mulative hazard rates for the combined outcome, in respect to 
treatment group, according to the Cox regression model (HR, 
0.95; 95% CI, 0.60–1.49; P=0.8) are reported.
Outcomes According to the Type of OAC Used 
in the Bridging and Nonbridging Groups
Of the 1780 included patients, 1219 were treated with NOACs 
and 561 with VKAs. The combined outcome was observed in 
Table 2. Univariable Analysis: Differences in Outcomes at 90 Days Between 
Patients Treated With Bridging With Low-Molecular-Weight Heparin and Those 
Without Bridging Therapy
Univariable Analysis 
(n=1780)
Bridging 
Therapy 
(n=371)
Nonbridging 
Therapy 
(n=1409) P Value
Combined outcome 42 (11.3%) 72 (5.1%) 0.0001
Ischemic outcome 29 (7.8%) 44 (3.1%) 0.0001
Hemorrhagic outcome 19 (5.1%) 32 (2.3%) 0.008
Table 3. Multivariable Analysis
Logistic Regression Analysis
 OR (95% CI) P Value
Bridging therapy (combined outcome) 2.3 (1.4–3.7) <0.0001
Bridging therapy (ischemic outcome) 2.2 (1.3–3.9) 0.005
Bridging therapy (hemorrhagic outcome) 2.4 (1.2–4.9) 0.01
Adjusted for NIHSS score, diabetes mellitus, arterial hypertension, 
dyslipidemia, paroxysmal AF, pacemaker; lesion size, leukoaraiosis, CHA
2
DS
2
-
VASc score after the event, history of stroke or TIA, type of oral anticoagulant 
(VKA vs NOAC), current smoking, congestive heart failure, and myocardial 
infarction; differences in outcomes at 90 d between patients treated with 
bridging with LMWH and those without bridging therapy. AF indicates atrial 
fibrillation; LMWH, low-molecular-weight heparin; NIHSS, National Institutes of 
Health Stroke Scale; NOAC, non–vitamin K antagonist oral anticoagulant; OR, 
odds ratio; and VKA, vitamin K antagonist.
Table 4. PS Matching: Outcomes
 
No 
Bridging 
Therapy 
(n=323)
Bridging 
Therapy 
(n=323) HR (95% CI) P Value
Combined 
outcome
13 (4.0%) 40 (12.3%) Unadjusted, 3.08 
(95% CI, 1.68–5.64)
0.0001
Adjusted, 2.23 (95% 
CI, 1.41–3.52)
0.0001
Ischemic 
outcome
6 (1.9%) 27 (8.3%) Unadjusted, 4.50 
(95% CI, 1.88–10.75)
0.003
Adjusted, 2.23 (95% 
CI, 1.29–3.88)
0.003
Hemorrhagic 
outcome
7 (2.2%) 19 (5.9%) Unadjusted, 2.71 
(95% CI, 1.16–6.37)
0.017
Adjusted, 2.24 (95% 
CI, 1.15–4.36)
0.017
HR indicates hazard ratio; and PS, propensity score.
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62 (5.1%) and 52 (9.3%) patients, respectively (P=0.01). An 
ischemic outcome was observed in 35 (2.9%) and 38 (6.8%) 
of the patients treated with NOACs of VKA, respectively 
(P=0.0001). The NOAC and VKA groups did not differ con-
cerning the hemorrhagic events that were 29 (2.4%) and 22 
(3.9%), respectively.
In the bridging group, 120 patients were treated with 
NOACs and 251 with VKAs; in the nonbridging group, 
1099 patients were treated with NOACs and 310 with VKAs. 
Within each group, no statistically significant differences 
were observed in either the combined outcome or the hemor-
rhagic event rate according to the type of OAC used. However, 
a statistically significant difference was observed for the rate 
of ischemic events in the nonbridging group: 27 events (2.5%) 
in patients treated with NOACs versus 17 events (5.5%) in 
patients treated with VKAs (P=0.015).
When stratifying each group according to the type of 
OAC, no statistically significant differences were observed 
between and within each group in outcome rates.
Discussion
This combined analysis of the RAF and RAF-NOACs data 
suggested that bridging therapy was associated with overall 
higher risks of early ischemic recurrence and symptomatic 
intracranial bleeding, independently of the type of OACs 
administered. The latter finding is in line with that reported by 
IST (International Stroke Trial),21 where an increase in hem-
orrhagic stroke was reported (1.2% for heparin versus 0.4% 
for aspirin). In the Outcomes Registry for Better Informed 
Treatment of Atrial Fibrillation, incidence of myocardial in-
farction, stroke or systemic embolism, major bleeding, hos-
pitalization, or death within 30 days was also significantly 
higher in patients receiving bridging therapy (13% versus 
6.3%; adjusted OR, 1.94; P=0.0001).22
Bridging therapy with heparin is sometimes started in sub-
acute ischemic stroke, as it is thought to reduce the risk of 
ischemic recurrence because of a possible prothrombotic ac-
tivity of warfarin at treatment initiation.23 However, reliable 
data on warfarin’s role in blocking endogenous anticoagulants 
have yet to be proven. It is plausible that warfarin alone might 
be more effective than bridging therapy with warfarin in the 
subacute phase of AF-associated stroke.
Another possible explanation of the increased ischemic 
stroke risk of heparin may be its underdosing as patient body 
weights are generally based on estimation. Moreover, our 
study did not allow to distinguish between ischemic recur-
rence in a different vascular territory from the index stroke, 
and recurrence in the same vascular territory, that may have 
been a progression of the first ischemia.24
In our study, bridging therapy with NOACs was also as-
sociated with a higher rate of ischemic events compared with 
those receiving NOACs alone. Besides RAF-NOAC, there 
are only a few prospective data available from observational 
studies on the safety and efficacy of early secondary preven-
tion using NOACs after cardioembolic stroke. Of these, the 
SAMURAI-NVAF study (Stroke Acute Management With 
Urgent Risk-Factor Assessment and Improvement-NVAF) 
reported that no intracerebral hemorrhage was recorded after 
an NOAC initiation within a median of 4 days poststroke,25 
whereas another observational study reported no significant 
difference in the rate of recurrent ischemic events when com-
paring early NOAC treatment within 7 days and after 7 days.26 
Ongoing studies such as the Timing of Oral Anticoagulant 
Therapy in Acute Ischemic Stroke With Atrial Fibrillation27 
and the ELAN (Early Versus Late Initiation of Direct Oral 
Anticoagulants in Post-Ischaemic Stroke Patients With 
Atrial Fibrillation Study28) are designed to estimate the ben-
efit of early versus late initiation of NOACs in patients with 
acute ischemic stroke related to AF without bridging therapy. 
Regarding the use of antiplatelets before initiating oral anti-
coagulation, 11.0% of bridging and 13.9% of nonbridging 
patients had been prescribed aspirin or clopidogrel. Therefore, 
it does not seem plausible that the associations would signifi-
cantly increase bleeding risks in patients treated with LMWH.
When comparing bridging versus nonbridging outcomes 
associated with OAC type, the risk profile associated with 
bridging appeared similar between NOACs and VKAs, therein 
suggesting that bridging therapy should be avoided particu-
larly in patients who will be treated with NOACs in secondary 
prevention (see Cox regression survival curve, Figure II in the 
online-only Data Supplement).
An analysis of the patient profiles indicated that older 
patients (mean age, 76.1 versus 73.0 years), those with leu-
koaraiosis or with large anterior circulation lesions, were less 
likely to receive bridging therapy. This might reflect a routine 
use of LMWH in only selected cases, since leukoaraiosis and 
large infarct volume are clinical predictors of both sympto-
matic and asymptomatic HT,29–31 both spontaneous29 and after 
thrombolytic therapy.32
However, based on our study results, there seems to be 
still overuse of LMWH because of a nonadherence to current 
guidelines. This overuse may also be because of the slower re-
versal of VKA and to the absence, at the time of enrollment of 
the RAF and RAF-NOACs, of an antidote for NOACs in case 
of bleeding.33 Regarding the choice of patients to be treated 
with bridging therapy, there could have been a selection bias. 
Moreover, unrecorded factor that can sway clinician decisions 
on the use of bridging therapy may include dysphagia in acute 
stroke phase, preferring subcutaneous-to-oral administrations.
A limitation of this analysis was that it was nonrandom-
ized; so it is possible that some confounding factors might 
have influenced the outcome results. We did not have infor-
mation on the exact time when international normalized ratio 
reached the target level in warfarin-treated patients. Moreover, 
the sizes of the 2 groups were not equally represented be-
cause only 20.5% of patients underwent bridging therapy 
with LMWH. Moreover, we are unable to specify the types 
of bleedings because the RAF and RAF-NOACs studies were 
not designed to collect such data.
In conclusion, our study suggests that the use of full-dose 
LMWH preceding oral anticoagulation in nonvalvular AF 
patients hospitalized for a recent ischemic stroke was associ-
ated with a higher risk of early ischemic recurrence and hem-
orrhagic events.
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